| |
| |
|
| Insider
Information: |
Paul Steven M |
| Relationship: |
|
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
1,185,025 |
|
|
Indirect Shares
|
632,151 |
|
|
| Direct
Value |
$37,673,864 |
|
|
|
Indirect Value
|
$30,104,525 |
|
|
| Total
Shares |
1,817,176 |
|
|
| Total
Value |
$67,778,389 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Eli Lilly & Co |
LLY |
EVP, Science and Techn... |
2010-02-01 |
38,897 |
2010-02-01 |
39,040 |
Premium* |
|
|
Sigma-Aldrich Corp |
SIAL |
Director |
2015-11-18 |
0 |
2007-01-02 |
0 |
Premium* |
|
|
Sage Therapeutics, Inc. |
SAGE |
|
2019-03-21 |
272,777 |
2022-11-28 |
593,111 |
Premium* |
|
|
Alnylam Pharmaceuticals Inc |
ALNY |
Director |
2022-04-01 |
1,000 |
2015-01-26 |
0 |
Premium* |
|
|
Voyager Therapeutics, Inc. |
VYGR |
President and CEO, Dir... |
2016-01-14 |
872,351 |
|
0 |
Premium* |
|
|
Karuna Therapeutics, Inc. |
KRTX |
|
2024-03-18 |
0 |
2024-03-18 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
131 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2009-12-23 |
5 |
GD |
$0.00 |
$0 |
D/D |
28,854 |
5,000 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2007-05-30 |
5 |
GA |
$0.00 |
$0 |
I/I |
4,665 |
5,735 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2006-09-15 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,070 |
5,906 |
0 |
- |
|
| SIAL |
Sigma-Aldrich Corp |
Director |
– • – |
2011-01-03 |
4 |
A |
$67.30 |
$80,760 |
D/D |
1,200 |
6,000 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2007-12-04 |
5 |
GA |
$0.00 |
$0 |
I/I |
1,774 |
7,509 |
0 |
- |
|
| SIAL |
Sigma-Aldrich Corp |
Director |
– • – |
2014-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
373 |
7,573 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2004-09-27 |
5 |
GD |
$0.00 |
$0 |
D/D |
10,314 |
8,000 |
0 |
- |
|
| SIAL |
Sigma-Aldrich Corp |
Director |
– • – |
2015-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
684 |
8,257 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2007-02-12 |
4 |
S |
$54.38 |
$396,430 |
I/I |
(7,290) |
8,359 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2008-02-11 |
5 |
GA |
$0.00 |
$0 |
I/I |
1,044 |
8,553 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2009-12-22 |
5 |
GA |
$0.00 |
$0 |
I/I |
8,553 |
8,553 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
President & CEO |
• • – |
2019-06-28 |
4 |
B |
$22.86 |
$230,424 |
D/D |
10,000 |
10,000 |
2.81 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
|
– • – |
2024-03-01 |
4 |
GD |
$0.00 |
$0 |
I/I |
60,608 |
10,000 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
|
– • – |
2024-02-09 |
4 |
D |
$317.14 |
$254,981 |
D/D |
(804) |
10,596 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
CSO and President of R&D |
• • – |
2023-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
11,400 |
11,400 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2007-02-09 |
4 |
GA |
$0.00 |
$0 |
I/I |
14,579 |
15,649 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2020-12-18 |
4 |
OE |
$9.30 |
$139,500 |
D/D |
15,000 |
16,000 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2022-04-01 |
4 |
OE |
$11.33 |
$169,950 |
D/D |
15,000 |
16,000 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2005-07-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
87 |
16,827 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2005-05-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
86 |
16,914 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2004-06-02 |
5 |
D |
$74.74 |
$46,115 |
D/D |
(617) |
18,314 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2004-06-02 |
5 |
GD |
$0.00 |
$0 |
D/D |
1,383 |
18,931 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and TechnologyOff |
• – – |
2003-07-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,504 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2005-10-13 |
4 |
OE |
$23.41 |
$99,997 |
D/D |
4,272 |
21,099 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2003-12-17 |
5 |
GD |
$0.00 |
$0 |
I/I |
213 |
28,448 |
0 |
- |
|
131 Records found
|
|
Page 2 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
